Company intelligence / Profile preview

Changshan Kaijiejian Biopharmaceutical Research and Development (Hebei) Co., Ltd.

Ownership: Private
Development stage: Other

Overview

Ebenatide (CJC-1134-PC, also known as albenatide), a long-acting GLP-1 analogue peptide, has shown positive effects on glycemic control (reduced HbA1c, MBG, TAR; improved TIR) and body composition in T2DM patients over 52 weeks in a clinical trial. A new Phase 3 trial in antidiabetic treatment-naive T2DM patients is ongoing.

Therapeutic areas: Endocrinology
Modalities: Peptides
Industry: Biotech

Partnerships

ConjuChem LLC

Beyond the preview

Go deeper on Changshan Kaijiejian Biopharmaceutical Research and Development (Hebei) Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Changshan Kaijiejian Biopharmaceutical Research and Development (Hebei) Co., Ltd..